- WKN: A0KF6M
- ISIN: DE000A0KF6M8
- Land: Deutschland
Nachricht vom 26.05.2021 | 07:30
HanseYachts Aktiengesellschaft: Interim Report of the management on the third quarter of 2020/2021
DGAP-News: HanseYachts Aktiengesellschaft
/ Key word(s): 9 Month figures/Quarterly / Interim Statement
HANSEYACHTS AG: INTERIM REPORT OF THE MANAGEMENT ON THE THIRD QUARTER OF 2020/2021
- Record order backlog of EUR 163.5 million as of 03/31/2021 (PY: EUR 81.7 million, +100%)
- Revenues and earnings temporarily weighed down by bottlenecks in supply chains and effects of the coronavirus pandemic
- Excellent liquidity in uncertain times
The order backlog as of 31 March 2021 rose by EUR 81.8 million or more than 100% to EUR 163.5 million from the year-ago level of EUR 81.7 million. The strong order intake can be attributed to the desire of end customers to have a coronavirus-free sanctuary on the water. Other factors contributing to the highly positive development include the company's successful switch to digital sales channels, the historically evolved, loyal customer base, and the continuous technical advancement of the 50 different yacht models of all six brands.
Financial performance in the third quarter
Due to the exceptional negative factors described above, EBITDA came to EUR -4.8 million in the first nine months of 2020/2021 (Q1-Q3 2019/2020: EUR -2.0 million). Depreciation and amortization of noncurrent assets amounted to EUR 4.3 million as of 31 March 2021. The financial result was unchanged at EUR -1.0 million. Including income taxes, the consolidated net loss amounted to EUR -10.5 million (Q1-Q3 2019/2020: EUR -7.5 million).
The EUR 3.0 million decrease in net income resulted particularly from the effects of the coronavirus pandemic, which adversely impacted the production of HanseYachts AG in the entire reporting period. Thanks to strict hygiene protocols, however, the boatyard was never completely shut down in the reporting period; instead, it was only necessary to stop individual production lines for a limited period of time.
The equity ratio came to 8.6 % as of 31 March 2021 (31 March 2020: 13.3%).
In view of existing yacht orders and the current manufacturing situation, the Executive Board expects that revenues in the current 2020/2021 financial year will be modestly lower than in the previous year. Moreover, the company's total operating performance should be lower than in 2019/2020 due to a marginal decrease in inventories of finished goods. This outlook is particularly based on the fact that the final quarter of the year is traditionally when the company generates strong revenues with high profit margins and the expectation that operational improvements and other productivity enhancements will take effect in the fourth quarter. Due to exceptional charges, the Executive Board expects that the EBITDA for the full year 2020/21 will be below the level of the previous year. After depreciation, amortization and interest, the Executive Board expects a consolidated net loss of an amount in the single-digit millions. This would be, as expected, a considerable improvement over the previous year's consolidated net loss (financial year 2019/2020: EUR -15.9 million), which included a substantial impairment of goodwill in the amount of EUR 11.7 million.
1) 2019/2020: Including the first-time consolidation of Privilège Marine SAS
2) 2016/2017: Adjusted for non-recurring income EUR 2.2 million from the reversal of an earlier impairment
|Ladebower Chaussee 11|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart|
|EQS News ID:||1200462|
|End of News||DGAP News Service|
HanseYachts Aktiengesellschaft: Interim Report ...
HanseYachts Aktiengesellschaft: Veröffentlichu ...
HanseYachts AG: Bekanntmachung der Einberufung ...
HanseYachts AG: Preliminary announcement of th ...
HanseYachts AG senkt EBITDA-Prognose für das G ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
01. Dezember 09:00 Trading-Tipp Jenoptik: Mit neuen Zielen zu neuen Höhen
01. Dezember 09:30 Adler Group: Kommt jetzt die Wende?
01. Dezember 09:50 Nel: Aktie kurz vor doppeltem Kaufsignal
01. Dezember 10:16 Commerzbank schießt nach oben – kaufen oder warten?
01. Dezember 11:15 Lufthansa: Aktie mit Lebenszeichen – Grund zur Freude?
News im Fokus
Fresenius Medical Care AG & Co. KGaA passt Besetzung des Vorstands an neues Betriebsmodell an
01. Dezember 2021, 08:30
Capital Markets Day
08. Dezember 2021
Original-Research: Rock Tech Lithium Inc. (von Montega AG): Kaufen Rock Tech Lithium Inc.
01. Dezember 2021